Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences With Self-Infusion, Home Providers, and Clinics.

ABSTRACT:

Background

Currently approved therapies for individuals with alpha-1 antitrypsin deficiency (AATD) are intravenously infused products. The burdens and demographics of infusion practices in the United States are not well-characterized.

Research question

What is the prevalence of different infusion practices in the United States?

Study design and methods

AlphaNet disease management participants completed a survey that captured current and past infusion practices. Data regarding the reasons for choosing their current infusion practice, problems with past infusion practices, resources required, and support services utilized were collected from February 8, 2022 through July 1, 2022.

Results

Among 5266 individuals, infusions happened at home by health care providers

SUBMITTER: Strange C 

PROVIDER: S-EPMC10699483 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature